Table 2.
Potential drug-drug interactions of remdesivir with COVID-19 treatment regimens and with drugs for comorbidities.
| Drug | Process Modified | Potential Outcome |
|---|---|---|
| Drugs Affecting Remdesivir ADME | ||
| Amiodarone [52,53,54] | Inhibition of P-gp and CYP | Increased remdesivir concentration |
| Chloroquine [55,56] | Inhibition of P-gp | Increased remdesivir concentration |
| Fluoxetine, Grapefruit juice [57] | Inhibition of CES | Increased remdesivir concentration |
| Dexamethasone, Rifampin [58] | Induction of CES | Decreased remdesivir concentration |
| Phenytoin, St. John’s Wort [52,59] | Induction of CYP3A4 | Decreased remdesivir concentration |
| Lopinavir-ritonavir [46] | Inhibition of CYP3A4 | Increased remdesivir concentration |
| Drugs Affected by Remdesivir | ||
| Theophylline [15,18,24] | Induction of CYP1A2 | Decreased theophylline concentration |
| Olmesartan [15,18,24] | Inhibition of OATP 1B1/1B3 transporters | Increased olmesartan concentration |
| Warfarin [15,18,24] | Inhibition of CYP2C9 | Increased warfarin concentration |
| Irinotecan [15,18,24] | Inhibition of OATP 1B1 | Increased irinotecan concentration |
| Atorvastatin [15,18,24] | Inhibition of CYP3A4 | Increased atorvastatin concentration |
| Metformin [15,18,24] | Inhibition of MATE1 | Increased metformin concentration |